Publications
803 results found
Calderon MA, Penagos M, Durham SR, 2014, Sublingual Immunotherapy for Allergic Rhinoconjunctivitis, Allergic Asthma, Food Allergy, and Prevention of Allergic Diseases, ALLERGENS AND ALLERGEN IMMUNOTHERAPY: SUBCUTANEOUS, SUBLINGUAL,AND ORAL, 5TH EDITION, Editors: Lockey, Ledford, Publisher: CRC PRESS-TAYLOR & FRANCIS GROUP, Pages: 361-380, ISBN: 978-1-84214-573-9
Shamji MH, Till SJ, Durham SR, 2014, Immunological Responses to Subcutaneous Allergen Immunotherapy, ALLERGENS AND ALLERGEN IMMUNOTHERAPY: SUBCUTANEOUS, SUBLINGUAL,AND ORAL, 5TH EDITION, Editors: Lockey, Ledford, Publisher: CRC PRESS-TAYLOR & FRANCIS GROUP, Pages: 51-65, ISBN: 978-1-84214-573-9
- Author Web Link
- Cite
- Citations: 1
Hopkinson N, Wallis C, Higgins B, et al., 2013, CIGARETTE PACKAGING Children must be protected from the tobacco industry's marketing tactics, BMJ-BRITISH MEDICAL JOURNAL, Vol: 347, ISSN: 1756-1833
- Author Web Link
- Cite
- Citations: 1
Bonini M, Di Mambro C, Calderon MA, et al., 2013, Beta<inf>2</inf>-agonists for exercise-induced asthma., The Cochrane database of systematic reviews, Vol: 10
It is well known that physical exercise can trigger asthma symptoms and can induce bronchial obstruction in people without clinical asthma. International guidelines on asthma management recommend the use of beta2-agonists at any stage of the disease. At present, however, no consensus has been reached about the efficacy and safety of beta2-agonists in the pretreatment of exercise-induced asthma and exercise-induced bronchoconstriction. For the purpose of the present review, both of these conditions are referred to by the acronymous EIA, independently from the presence of an underlying chronic clinical disease. To assess the effects of inhaled short- and long-acting beta2-agonists, compared with placebo, in the pretreatment of children and adults with exercise-induced asthma (or exercise-induced bronchoconstriction). Trials were identified by electronic searching of the Cochrane Airways Group Specialised Register of Trials and by handsearching of respiratory journals and meetings. Searches are current as of August 2013. We included randomised, double-blind, placebo-controlled trials of any study design, published in full text, that assessed the effects of inhaled beta2-agonists on EIA in adults and children. We excluded studies that did not clearly state diagnostic criteria for EIA. We used standard methodological procedures as expected by The Cochrane Collaboration. We included 53 trials consisting of 1139 participants. Forty-eight studies used a cross-over design, and five were performed in accordance with a parallel-group design. Forty-five studies addressed the effect of a single beta2-agonist administration, and eight focused on long-term treatment. We addressed these two different intervention regimens as different comparisons.Among primary outcomes for short-term administration, data on maximum fall in forced expiratory volume in 1 second (FEV1) showed a significant protective effect for both short-acting beta-agonists (SABA) and long-acting beta-agonists (LABA
Calderon MA, Penagos M, Carr VA, et al., 2013, Allergen injection immunotherapy for perennial allergic rhinitis: a Cochrane systematic review and meta-analysis, Annual Meeting of the British-Society-of-Allergy-and-Clinical-Immunology, Publisher: WILEY-BLACKWELL, Pages: 1431-1432, ISSN: 0954-7894
- Author Web Link
- Cite
- Citations: 1
Matsuoka T, Durham SR, Shamji MH, 2013, Interleukin 27-primed dendritic cells suppress grass pollen-specific Th2 responses in patients with seasonal allergic rhinitis, Annual Meeting of the British-Society-of-Allergy-and-Clinical-Immunology, Publisher: WILEY-BLACKWELL, Pages: 1438-1438, ISSN: 0954-7894
Pillai P, Fang C, Chan C, et al., 2013, Detection and quantitation of total and allergen specific IgE in the bronchial mucosa of atopic and non-atopic asthmatics, Annual Meeting of the British-Society-of-Allergy-and-Clinical-Immunology, Publisher: WILEY-BLACKWELL, Pages: 1441-1441, ISSN: 0954-7894
Charlesworth J, Goldstone A, Yan R, et al., 2013, Regulatory B cells are reduced amongst grass-pollen allergic patients compared with non-allergic controls, Annual Meeting of the British-Society-of-Allergy-and-Clinical-Immunology, Publisher: WILEY-BLACKWELL, Pages: 1429-1429, ISSN: 0954-7894
Matsuoka T, Shamji MH, Durham SR, 2013, Allergen Immunotherapy and Tolerance, ALLERGOLOGY INTERNATIONAL, Vol: 62, Pages: 403-413, ISSN: 1323-8930
- Author Web Link
- Cite
- Citations: 65
Till SJ, Raynsford EJ, Reynolds CJ, et al., 2013, Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation, Thorax, Vol: 69, Pages: 335-345, ISSN: 0040-6376
Eifan AO, Calderon MA, Durham SR, 2013, Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma, EXPERT OPINION ON BIOLOGICAL THERAPY, Vol: 13, Pages: 1543-1556, ISSN: 1471-2598
- Author Web Link
- Cite
- Citations: 56
Shamji MH, Francis JN, Wuertzen PA, et al., 2013, Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: Inhibition by blocking antibody responses after immunotherapy, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 132, Pages: 1003-+, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 45
Qaseem A, Pathan A, Layhadi J, et al., 2013, Recombinant human pulmonary surfactant protein-D (rhSP-D) modulates Th2 responses and suppresses IgE-facilitated allergen binding to B cells, EUROPEAN RESPIRATORY JOURNAL, Vol: 42, ISSN: 0903-1936
Calderon MA, Penagos M, Carr VA, et al., 2013, Allergen injection immunotherapy for perennial allergic rhinitis: Cochrane systematic review and meta-analysis, World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Publisher: WILEY-BLACKWELL, Pages: 643-644, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 1
Durham SR, Andersen JS, Li Z, et al., 2013, The influence of pollen exposure on efficacy measurements in grass allergy immunotherapy trials, World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Publisher: WILEY-BLACKWELL, Pages: 70-70, ISSN: 0105-4538
Shamji MH, Saleem N, Nicholson J, et al., 2013, Local nasal antiinflammatory IgG4 responses are induced following grass pollen sublingual and subcutaneous immunotherapy, World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Publisher: WILEY-BLACKWELL, Pages: 21-22, ISSN: 0105-4538
Qaseem AS, Pathan AA, Layhadi JA, et al., 2013, Recombinant human pulmonary surfactant protein-D (rhSP-D) modulates Th2 responses and suppresses IgE-facilitated allergen binding to B cells, World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Publisher: WILEY-BLACKWELL, Pages: 48-48, ISSN: 0105-4538
Cifuentes L, Ploetz S, Chaker A, et al., 2013, <i>In vitro</i> immunomonitoring of birch pollen-allergic patients during allergen-specific immunotherapy, World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Publisher: WILEY-BLACKWELL, Pages: 468-469, ISSN: 0105-4538
Shamji MH, Matsuoka T, Durham SR, 2013, IL-27 supresses allergen-driven TH2 responses and IL-27+dendritic cells are significantly reduced in grass pollen allergic individuals compared to non-atopic controls, World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Publisher: WILEY-BLACKWELL, Pages: 23-23, ISSN: 0105-4538
Shamji MH, Layhadi JA, Scadding GW, et al., 2013, A novel subset of regulatory T cells: interleukin-35 producing T regs (iTR35) are induced after grass pollen sublingual immunotherapy, World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Publisher: WILEY-BLACKWELL, Pages: 67-67, ISSN: 0105-4538
Slovick A, Douiri A, Kelly J, et al., 2013, Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE)., Clin Transl Allergy, Vol: 3, ISSN: 2045-7022
BACKGROUND: Subcutaneous immunotherapy with high dose grass pollen (typically microgram quantities) was first described over 100 years ago. This treatment suppresses allergen-induced cutaneous late responses, with lesser effects on early responses. We previously reported that repeated 2-weekly intradermal injections of grass pollen - containing approximately 7 ng of major allergen Phl p 5 - led to a progressive suppression of the allergen-induced cutaneous response, and that by the sixth injection, this was inhibited by over 90%. The purpose of this trial is to investigate the clinical efficacy of intradermal desensitisation with low doses (i.e. nanogram quantities) of grass pollen allergen for seasonal allergic rhinitis. METHODS/DESIGN: The Pollen Low dose Intradermal therapy Evaluation (PollenLITE) is a single centre double-blind randomised parallel group controlled trial of the efficacy and safety of intradermal grass pollen injections plus standard treatment, versus histamine injections plus standard treatment, in adults with moderate-severe grass pollen-induced allergic rhinitis ('summer hay fever'). A minimum of ninety adults with a history of moderate-severe persistent allergic rhinitis during the UK grass pollen season will be randomised into two equal groups to receive 7 or 8 intradermal injections of grass pollen extract (containing approximately 7 ng of major allergen Phl p 5) or histamine, before the grass pollen season. In the summer, participants will score their symptoms, medication requirements, visual analogue scores, and complete EuroQOL (EQ-5D-5 L) and mini Rhinoconjunctivitis Quality of Life Questionnaires. Global assessments will also be recorded at the end of the pollen season. Blood samples will be collected from all participants for mechanistic immune assays. Skin punch biopsies will also be collected in 40 participants selected at random from intradermal injection sites after the grass pollen season for mechanistic assays
Stott B, Lavender P, Lehmann S, et al., 2013, Human IL-31 is induced by IL-4 and promotes T<sub>H</sub>2-driven inflammation, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 132, Pages: 446-+, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 121
Skypala IJ, Bull S, Deegan K, et al., 2013, The prevalence of PFS and prevalence and characteristics of reported food allergy; a survey of UK adults aged 18-75 incorporating a validated PFS diagnostic questionnaire, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 43, Pages: 928-940, ISSN: 0954-7894
- Author Web Link
- Cite
- Citations: 41
Passalacqua G, Baena-Cagnani CE, Bousquet J, et al., 2013, Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 132, Pages: 93-98, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 118
Petalas K, Durham SR, 2013, Allergen immunotherapy for allergic rhinitis, RHINOLOGY, Vol: 51, Pages: 99-110, ISSN: 0300-0729
- Author Web Link
- Cite
- Citations: 31
Bufe A, Eberle P, Tholstrup B, et al., 2013, Clinical efficacy and immunological response in children is similar to that of adults after the first treatment season with SQ-standardized grass allergy immunotherapy tablet in two randomized trials, Allergologie, Vol: 36, Pages: 238-245, ISSN: 0344-5062
Background: Specific immunotherapy is the only treatment of IgE-mediated allergic diseases with the potential to modify the underlying cause of disease and prevent disease progression or even cure the disease. Treatment in children is therefore desirable. However, it is an open question whether immunotherapy in children and adolescents works as effective as demonstrated in adults. Objective: This post-hoc study compares the clinical efficacy and immunological response in children and adults based on two separate randomized, double-blind, placebocontrolled trials with the SQ-standardized grass allergy immunotherapy tablet (AIT) (ALK, Denmark). Methods: Children and adults were treated with grass AIT or placebo prior to and during one grass pollen season. To account for seasonal and geographical variabilities in grass pollen counts between trials, data for the peak 2 weeks of the grass pollen season has been compared. Endpoints included rhinoconjunctivitis symptom scores, medication scores and percentages well-days. Furthermore results for the entire pre- and co-seasonal periods of each trial in Phleum pratense-specific IgE-blocking factor and IgG4 have been compared. Results: The measured treatment efficacy during the peak grass pollen season from the pediatric and the adult trials were similar in difference relative to placebo for symptom scores (27%; 28%; p-values for both <0.01), medication scores (64%; 56%; p-values for both <0.01) and percentages of well-days (44%; 46%; p-values for both <0.01). Grass AIT induced comparable IgE-blocking factor and IgG4 responses in children and adults. All assessments were in favor of active treatment. Conclusion: Treatment with grass AIT for one grass pollen season is as efficacious in children as in adults and induces comparable immunological responses. © 2013 Dustri-Verlag Dr. Karl Feistle.
Varga E-M, Kausar F, Aberer W, et al., 2013, Tolerant beekeepers display venom-specific functional IgG<sub>4</sub> antibodies in the absence of specific IgE, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 131, Pages: 1419-1421, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 40
Marth K, Breyer I, Focke-Tejkl M, et al., 2013, A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS-Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype, JOURNAL OF IMMUNOLOGY, Vol: 190, Pages: 3068-3078, ISSN: 0022-1767
- Author Web Link
- Cite
- Citations: 53
Pilette C, Jacobson MR, Ratajczak C, et al., 2013, Aberrant dendritic cell function conditions Th2-cell polarization in allergic rhinitis, ALLERGY, Vol: 68, Pages: 312-321, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 63
Hopkinson NS, Moxham J, Montgomery H, et al., 2013, Tobacco industry lobbyists and their health-care clients, LANCET, Vol: 381, Pages: 445-445, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 3
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.